Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35180 participants
INTERVENTIONAL
2021-02-01
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators study factors that could potentially influence public's trust in COVID-19 vaccines through a large-scale online field experiment. The investigators conduct an online survey of 32,400 subjects in nine countries (USA, Brazil, Mexico, China, India, Indonesia, Russia, Germany, and UK).
The investigators study how willingness to receive the COVID-19 vaccine is affected by (1) the "novelty" of the vaccine technology (conventional vs. RNA vaccines), and (2) the adoption rate of the new vaccine in the country. That is - the impact of controversial science and the force of conformity on the rates of adoption. The latter will also allow us to calculate the "tipping point" adoption rate for each country that will allow the country to achieve herd immunity from COVID-19.
The investigators have four hypotheses, below.
H1 (Conformity): People are more willing to receive a vaccine as the cumulative adoption rate in their community increases.
H2 (Novelty): People are less willing to get a COVID-19 vaccine that uses the new RNA technology, compared to a conventional vaccine
H3 (Interaction between H1 and H2): As the cumulative adoption rate in a community increases, the difference between people's willingness to adopt conventional rather than RNA vaccines decreases.
H4 (Tipping Point): Each country will have a different "tipping point". This is the cumulative adoption rate after which unvaccinated people are significantly more willing to get the vaccine. Countries that have a higher "honesty index" will have the tipping point appear at a lower cumulative adoption rate.
Please note that this study is not a clinical trial. This study is a randomized controlled trial in the form of an online survey.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Vaccine Messaging, Part 1
NCT04460703
Educational Videos to Address Vaccine Hesitancy in Childhood Immunization
NCT05390697
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): Its' Correlation Factors and an Educational Intervention Programme
NCT04930185
Understanding the Immune Response to Meningitis Vaccines
NCT00901940
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An online survey is conducted across 9 countries with 3,600 subjects per country. About 15 questions will be asked for each subject and the survey is expected to take about 10-15 minutes to complete.
The 9 countries are USA, Brazil, Mexico, China, India, Indonesia, Russia, Germany and the UK. The three most populous countries from three major continents (Americas, Asia and Europe) are chosen. The target subjects are healthy adults over 18 years of age.
The survey instrument will consist of two parts. In the first part, the survey will ask 10 questions regarding their demographics and the general perception on the safety, effectiveness, and importance of vaccines. This part of the survey allows us to explore the relationship between the individual factors (such as age, gender or income status) and trust in COVID-19 vaccine, as well as to normalize the attitude towards COVID-19 vaccines over the overall vaccine-related confidence.
The 3 key questions of interest are:
"Suppose that a conventional vaccine for COVID-19 receives approval for human use and is available for the public.
A3. How much do you think the government should subsidize the conventional COVID-19 vaccine? \[10%, 25%, 50%, 75%, 100%\]
A4. If the conventional COVID-19 vaccine were provided to you for free, how likely are you to accept the vaccination? \[Very likely, somewhat likely, neither likely nor unlikely, somewhat unlikely, very unlikely\]
A5. Suppose the conventional COVID-19 vaccine is endorsed by your Government, free, but no one in your country has received the vaccine. How likely would you be willing to be vaccinated with this new vaccine? \[Very likely, somewhat likely, neither likely nor unlikely, somewhat unlikely, very unlikely\]"
The investigators manipulate two dimensions of information between the subjects. The two dimensions are:
* 2 vaccine types: 50% of subjects will be asked for "conventional vaccine"; 50% of subjects will be asked for "RNA vaccine"
* 5 different levels of adoption rate in the country: 0% (i.e., no one in your country has received the vaccine), 20%, 40%, 60%, and 80%
Within each country, there will be 2 (vaccine type) x 5 (different adoption rates) = 10 between-subject treatments.
In the second part of the survey, the investigators ask participants to complete a simple economic dice-rolling task, and predict outcomes of the same task in their own country. The investigators will study how individual performance in these tasks correlate with their trust in COVID-19 vaccines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional vaccine, 0% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 0%.
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
0% adoption rate
We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
Conventional vaccine, 20% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 20%.
20% adoption rate
We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
Conventional vaccine, 40% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 40%.
40% adoption rate
We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
Conventional vaccine, 60% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 60%.
60% adoption rate
We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
Conventional vaccine, 80% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 80%.
80% adoption rate
We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
RNA vaccine, 0% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 0%.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
0% adoption rate
We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
RNA vaccine, 20% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 20%.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
20% adoption rate
We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
RNA vaccine, 40% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 40%.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
40% adoption rate
We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
RNA vaccine, 60% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 60%.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
60% adoption rate
We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
RNA vaccine, 80% adoption rate
Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.
In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 80%.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
80% adoption rate
We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA vaccine
We elicit subjects' willingness to receive RNA COVID-19 vaccine
20% adoption rate
We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
40% adoption rate
We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
60% adoption rate
We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
80% adoption rate
We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
Conventional vaccine
We elicit subjects' willingness to receive conventional COVID-19 vaccine
0% adoption rate
We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University of Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ho Teck Hua
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teck Ho
Role: PRINCIPAL_INVESTIGATOR
National University of Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SurveyMonkey
San Mateo, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985 Nov 28-Dec 4;318(6044):323-9. doi: 10.1038/318323a0.
Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis. 2011 Apr 1;52(7):911-6. doi: 10.1093/cid/cir007.
Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020 Oct;20(10):583-584. doi: 10.1038/s41577-020-00451-5.
Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014 Apr 17;32(19):2150-9. doi: 10.1016/j.vaccine.2014.01.081. Epub 2014 Mar 2.
Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 Feb;27(2):225-228. doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20.
Olive JK, Hotez PJ, Damania A, Nolan MS. The state of the antivaccine movement in the United States: A focused examination of nonmedical exemptions in states and counties. PLoS Med. 2018 Jun 12;15(6):e1002578. doi: 10.1371/journal.pmed.1002578. eCollection 2018 Jun.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SG-Trust in Vaccines
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.